GLOBAL PHARMACEUTICAL INTERMEDIATES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global Pharmaceutical Intermediates Market, By Intermediate Type (Bulk Intermediate, Chemical Intermediate), By Application (Anti-Infective Drugs, Analgesics, Antidiabetic Drugs, Cardiovascular Drugs, Antimicrobial Drugs, Anti-inflammatory Drugs, Others), By End User (Biopharmaceutical Companies, CMO, CRO, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Mar 2024
Code : CMI6740
Pages :165
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Developments

On January 16, 2024, Willow Biosciences Inc., a leading biotechnology company dedicated to revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announced a collaboration with Enterin, Inc., a clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients (APIs).
In December 2023, Ami Organics Limited, a prominent global manufacturer of advanced pharmaceutical intermediates and specialty chemicals, announced that it has signed another definitive agreement with Fermion, a wholly-owned subsidiary of Orion Corporation, a globally operating pharmaceutical company, in Finland. As part of the arrangement, Ami Organics Limited will produce a couple of more advanced pharmaceutical intermediates for Fermion.
In March 2022, Sumitomo Chemical Co., Ltd., a prominent Japan-based chemical company, announced that it will build a new manufacturing unit for active pharmaceutical ingredients (APIs) and intermediates for small molecule pharmaceuticals at its Oita Works facility. This initiative aims to increase the company's capacity to deliver a wide range of high-quality APIs and intermediates in response to the growing demand for small molecule pharmaceuticals. The new plant is scheduled to come on stream in September 2024.
In February 2022, CordenPharma, a full-service CDMO, announced the successful acquisition of three production sites from Vifor Pharma, a global specialty pharmaceuticals company. The facilities will be renamed Corden Pharma Fribourg (with its Ettingen office) in Switzerland and Corden Pharma Lisbon in Portugal.